Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

odanacatib

- PMLiVE

Amgen’s Blincyto effective in broader leukaemia population

Could lead to further licences for the $178,000 blood cancer treatment

- PMLiVE

Novartis wins partial reprieve for Gilenya in Germany

IQWiG now minded to give a broader recommendation for the multiple sclerosis pill

Roche Basel Switzerland

Roche’s breakthrough PD-L1 drug slows cancer growth

Latest positive trial for the firm’s next-gen oncology product atezolizumab

Allergan logo

Allergan stumps up $375m for bolt-on acquisitions

Firm has recently added two migraine drugs and Oculeve to its portfolio

- PMLiVE

Novartis gets early approval for heart failure drug Entresto

It is the first worldwide indication for the in-class neprilysin inhibitor

- PMLiVE

90TEN and ICG win market research award at Communiqué 2015

Execution of 'Wheals of Despair' campaign for Novartis praised by judges

Novartis day

Novartis heart drug may see novel pricing plan

Swiss firm looking to risk share with payers based on clinical outcomes

- PMLiVE

Novartis launches Apple Watch app for the visually impaired

Upgraded ViaOpta app already works on iPhone and Android phones

- PMLiVE

Opdivo approved via UK’s early drug access scheme

Bristol-Myers Squibb’s immunotherapy the first lung cancer drug approved by EAMS

Novartis building

Novartis buys chronic pain specialist Spinifex Pharma

Pays $200m for the Australian pharmaceutical company

- PMLiVE

Ten new medicines recommended in Europe

Includes double approvals for rare disease specialist Alexion and Novartis

- PMLiVE

Google unveils wearable health tracker

Builds on the tech giant’s foray into the health and wellness sector

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links